Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms and the selective loss of dopaminergic neurons. The etiology of idiopathic PD is likely a combination of genetic and environmental factors. Despite findings from mammalian studies that have provided significant insight into the disorder, the molecular mechanisms underlying its pathophysiology are still poorly understood. The nematode Caenorhabditis elegans (C. elegans) is a powerful system for genetic analysis. Considering C. elegans short lifespan, fully sequenced genome, high genetic and neurobiochemical conservation with humans, as well as the availability of facile genetic tools, the nematode represents a highly efficient and effective model system to explore the molecular basis of PD. In this review we describe the utility of C. elegans for PD research, and the opportunity the model system presents to identify therapeutic targets.
Keywords: Nematode, dopamine, Parkinson’s disease, neurodegeneration, neuroprotection, dopaminergic neurons, mammalian studies, pathophysiology, Caenorhabditis, therapeutic targets.
CNS & Neurological Disorders - Drug Targets
Title:C. elegans as a Genetic Model System to Identify Parkinson's Disease- Associated Therapeutic Targets
Volume: 11 Issue: 8
Author(s): Julia Vistbakka, Natalia VanDuyn, Garry Wong and Richard Nass
Affiliation:
Keywords: Nematode, dopamine, Parkinson’s disease, neurodegeneration, neuroprotection, dopaminergic neurons, mammalian studies, pathophysiology, Caenorhabditis, therapeutic targets.
Abstract: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms and the selective loss of dopaminergic neurons. The etiology of idiopathic PD is likely a combination of genetic and environmental factors. Despite findings from mammalian studies that have provided significant insight into the disorder, the molecular mechanisms underlying its pathophysiology are still poorly understood. The nematode Caenorhabditis elegans (C. elegans) is a powerful system for genetic analysis. Considering C. elegans short lifespan, fully sequenced genome, high genetic and neurobiochemical conservation with humans, as well as the availability of facile genetic tools, the nematode represents a highly efficient and effective model system to explore the molecular basis of PD. In this review we describe the utility of C. elegans for PD research, and the opportunity the model system presents to identify therapeutic targets.
Export Options
About this article
Cite this article as:
Vistbakka Julia, VanDuyn Natalia, Wong Garry and Nass Richard, C. elegans as a Genetic Model System to Identify Parkinson's Disease- Associated Therapeutic Targets, CNS & Neurological Disorders - Drug Targets 2012; 11 (8) . https://dx.doi.org/10.2174/1871527311211080004
DOI https://dx.doi.org/10.2174/1871527311211080004 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nicotinic Cholinergic System in the Hypothalamus Modulates the Activity of the Hypothalamic Neuropeptides During the Stress Response
Current Neuropharmacology Emerging Synergisms Between Drugs and Physiologically-Patterned Weak Magnetic Fields: Implications for Neuropharmacology and the Human Population in the Twenty-First Century
Current Neuropharmacology Malaria Stage-Specific Vaccine Candidates
Current Pharmaceutical Design Snake Venom: From Deadly Toxins to Life-saving Therapeutics
Current Medicinal Chemistry Regulation of G-Protein-Coupled Receptor Signalling by the Scaffolding Proteins Spinophilin/Neurabin 2 and Neurabin 1
Current Chemical Biology Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy
Current Vascular Pharmacology Biosynthetic Pathways of Bioactive N-Acylethanolamines in Brain
CNS & Neurological Disorders - Drug Targets Regulation of Sulfotransferases by Xenobiotic Receptors
Current Drug Metabolism Ras Family Small GTPase-Mediated Neuroprotective Signaling in Stroke
Central Nervous System Agents in Medicinal Chemistry Improvement of Nerve Fiber Density in Fibromyalgia Patients Treated with IVIg
Current Rheumatology Reviews Adenosine Receptor Ligands-Recent Developments Part I. Agonists
Current Medicinal Chemistry Ethanol Withdrawal and Hyperalgesia
Current Drug Abuse Reviews Editorial [Hot Topic: Pain - Unmet Need and Emerging Targets & Therapies (Guest Editor: Sivaram Pillarisetti)]
CNS & Neurological Disorders - Drug Targets α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Developments in Selective Small Molecule ATP-Targeting the Serine/Threonine Kinase Akt/PKB
Mini-Reviews in Medicinal Chemistry The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications
Current Pharmaceutical Design Tenofovir-Related Nephropathies in HIV-Infected Patients
Current Vascular Pharmacology Pharmacogenomics and Sepsis-Induced Renal Failure: Effects of β 2-Adrenoceptor Function on the Course of Sepsis
Current Pharmacogenomics and Personalized Medicine Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Melanoma
Current Cancer Therapy Reviews